Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: liraglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT01890993

ENCEPP/SDPP/8135 (Other Identifier)

U1111-1142-2764 (Other Identifier)

NN2211-4077

Details and patient eligibility

About

This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.

Enrollment: 952 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients treated with liraglutide or DPP-4 inhibitors, according to license in respective participating country with data available for 12 (+/- 2) months

Exclusion criteria

• Patients treated with liraglutide or DPP-4 inhibitors, outside of license in respective participating country

Trial design

952 participants in 2 patient groups

Liraglutide

Treatment:

Drug: liraglutide

DPP-4

Treatment:

Drug: liraglutide